Tempest Therapeutics is actively seeking strategic partnerships to advance its liver cancer drug amezalpat to Phase III trials after positive Phase II results showed a six-month improvement in overall survival.
Tempest Therapeutics received FDA clearance to proceed with a Phase 2 clinical trial of TPST-1495, a novel dual receptor inhibitor of prostaglandin signaling, for treating Familial Adenomatous Polyposis (FAP).
Amezalpat, a PPARα antagonist, receives Fast Track Designation from the FDA, following its prior Orphan Drug Designation for hepatocellular carcinoma (HCC).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.